We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AVEO Pharmaceuticals Inc | NASDAQ:AVEO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.00 | 14.99 | 15.00 | 0 | 01:00:00 |
From May 2022 to May 2024
By Kwanwoo Jun
South Korea's LG Chem Ltd. has decided to acquire U.S. biotech company AVEO Pharmaceuticals Inc. for $566 million to enter the U.S. cancer treatment market.
The acquisition deal will be completed by the first quarter of 2023, LG Chem said in a regulatory filing late Tuesday after its board approved it.
The deal still needs approval from AVEO shareholders and U.S. regulators for its completion, LG Chem said.
The planned acquisition is the latest in LG Chem's push to diversify its previously petrochemicals-focused business into biotech and other industries.
AVEO Pharmaceuticals said it was marketing Fotivda, a prescription medicine used to treat adults with advanced kidney cancer, in the U.S.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
October 18, 2022 05:50 ET (09:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AVEO Pharmaceuticals Chart |
1 Month AVEO Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
